阅读时间：3分钟
亨茨曼癌症研究所 research highlights shine the spotlight on new discoveries 和 cutting-edge cancer research. 2023年3月, researchers administered a I期临床试验 investigating a new targeted therapy to its first patient. 也, new evidence showed elephant genes can function to induce death of human cancer cells, 和 a pair of grants will fund research on 慢性淋巴细胞白血病 和 vaccine hesitancy 和 confidence of those in the 服务区域.
I期临床试验 for new targeted therapy enrolls first patient
Vaia Florou，医学博士, physician-scientist at 亨茨曼癌症研究所, enrolled the first patient in the world on her I期临床试验 testing a new targeted therapy for cancer. The drug, an Aurora kinase A inhibitor, blocks cancer growth. While the therapy is currently being used for any solid tumors, 一旦找到正确的剂量, Florou’s team can 研究 the drug in more specific cancer types. They will do this by enrolling more patients 和 sorting them into cancer types, where they will watch how the drug interacts with the tumors. 亨茨曼癌症研究所 is one of a few cancer centers that can accommodate I期临床试验s, which are a way for patients to participate in research 和 get access to new therapies.
Elephant gene discovered to kill cancer cells
在一个 研究 published in the Nature journal Cell Death Discovery, researchers found that a processed copy of a unique elephant gene, TP53-RETROGENE 9, 能杀死人类癌细胞吗. Lisa Abegglen博士 和 约书亚希夫曼，医学博士, researchers at 亨茨曼癌症研究所, 和 their team explored how TP53-RETROGENE 9 能杀死人类癌细胞吗 through the mitochondria, 细胞的发电站. When a cell has DNA damage, it should either repair itself or die. If the damaged cell cannot repair itself, then DNA damage-response genes like human TP53 should recognize it 和 cause the cell to die. If they don’t, cells can become cancer. 在实验室环境中, the team found th在 elephant gene, when expressed in human cancer cells, 诱导细胞死亡. This discovery suggests that elephant TP53 retrogenes are functional, despite previous reports th在y are non-functional pseudogenes. Dr. Abegglen 和 colleagues are considering how this special elephant gene could be useful in cancer treatment.
New grant provides support to clinical investigator to research 慢性淋巴细胞白血病
The National Cancer Institute granted a new R50 award to Deborah Stephens, DO, physician-scientist at 亨茨曼癌症研究所. Through the SWOG national cooperative cancer research groups, Stephens is leading a national clinical trial for patients with 慢性淋巴细胞白血病 (CLL). A second clinical trial for patients whose CLL transforms into more aggressive lymphoma will open in the next two years. She will also continue her active work in national CLL cancer research groups 和 committees. The five-year R50 award provides protected research time for clinical investigators who are actively working on cooperative group national studies.
Underst和ing vaccine hesitancy 和 confidence in the Mountain West
迪安娜·凯普卡，博士，公共卫生硕士, investigator at 亨茨曼癌症研究所 和 Associate Professor in the 犹他大学 College of Nursing, received a Merck Investigator Studies Program (MISP) grant to 研究 many domains of vaccine hesitancy 和 confidence in the Mountain West with a survey of young adults. The Mountain West contains many rural areas that generally have lower adolescent 和 young adult vaccination rates than other areas in the United States. The 研究 will also use the Utah Statewide Immunization Information System to develop 和 examine an intervention to build confidence in vaccines with children 和 young adults enrolled in Utah’s Vaccines for Children Program.
媒体接触
希瑟·西蒙森
公共事务高级经理
亨茨曼癌症研究所
801 581-3194
公共.affairs@hci.犹他州.edu
关于亨斯迈癌症研究所 在 犹他大学
亨茨曼癌症研究所 在 犹他大学 is the National Cancer Institute-designated Comprehensive Cancer Center for Utah, 爱达荷州, 蒙大拿, 内华达, 和怀俄明州. With a legacy of innovative cancer research, 突破性的发现, 世界一流的病人护理, we are transforming the way cancer is understood, 预防, 诊断, 治疗, 并存活下来. 亨茨曼癌症研究所 focuses on delivering the most advanced cancer healing 和 prevention through scientific breakthroughs 和 cutting-edge technology to advance cancer treatments of the future beyond the st和ard of care today. 大发娱乐有超过 300项公开临床试验 和 250个研究小组 研究癌症. More genes for inherited cancers have been discovered at 亨茨曼癌症研究所 than at any other cancer center. Our scientists are world-renowned for underst和ing how cancer begins 和 using that knowledge to develop innovative approaches to treat each patient’s unique disease. 亨茨曼癌症研究所 was founded by Jon M. 和卡伦·亨茨曼.